<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher
  PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Humana Press</PublisherName>
    <PublisherLocation>Totowa, NJ</PublisherLocation>
    <PublisherImprintName>Humana Press</PublisherImprintName>
  </PublisherInfo>
  <Series>
    <SeriesInfo SeriesType="Series" TocLevels="0">
      <SeriesID>7651</SeriesID>
      <SeriesPrintISSN>1064-3745</SeriesPrintISSN>
      <SeriesElectronicISSN>1940-6029</SeriesElectronicISSN>
      <SeriesTitle Language="En">Methods in Molecular Biology™</SeriesTitle>
      <SeriesSubTitle Language="En">Methods and Protocols</SeriesSubTitle>
      <SeriesAbbreviatedTitle>Methods Molecular Biology</SeriesAbbreviatedTitle>
    </SeriesInfo>
    <Book Language="En">
      <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterContentSeparately" OutputMedium="All" TocLevels="0">
        <BookID>978-1-60327-931-4</BookID>
        <BookTitle>Neural Cell Transplantation</BookTitle>
        <BookSubTitle>Methods and Protocols</BookSubTitle>
        <BookVolumeNumber>549</BookVolumeNumber>
        <BookSequenceNumber>549</BookSequenceNumber>
        <BookDOI>10.1007/978-1-60327-931-4</BookDOI>
        <BookTitleID>160368</BookTitleID>
        <BookPrintISBN>978-1-60327-930-7</BookPrintISBN>
        <BookElectronicISBN>978-1-60327-931-4</BookElectronicISBN>
        <BookEdition>1</BookEdition>
        <BookChapterCount>16</BookChapterCount>
        <BookCopyright>
          <CopyrightHolderName>Humana Press</CopyrightHolderName>
          <CopyrightYear>2009</CopyrightYear>
        </BookCopyright>
        <BookSubjectGroup>
          <BookSubject Code="L" Type="Primary">Life Sciences</BookSubject>
          <BookSubject Code="L16008" Priority="1" Type="Secondary">Cell Biology</BookSubject>
          <BookSubject Code="L16010" Priority="2" Type="Secondary">Stem Cells</BookSubject>
          <SubjectCollection Code="SUCO11642">Biomedical and Life Sciences</SubjectCollection>
        </BookSubjectGroup>
        <BookContext>
          <SeriesID>7651</SeriesID>
        </BookContext>
      </BookInfo>
      <BookHeader>
        <EditorGroup>
          <Editor>
            <EditorName DisplayOrder="Western">
              <GivenName>David</GivenName>
              <FamilyName>Gordon</FamilyName>
            </EditorName>
            <Contact>
              <Email>d.gordon@bristol.ac.uk</Email>
            </Contact>
          </Editor>
          <Editor>
            <EditorName DisplayOrder="Western">
              <GivenName>Neil J.</GivenName>
              <FamilyName>Scolding</FamilyName>
            </EditorName>
            <Contact>
              <Phone>+440177918-6632</Phone>
              <Email>n.j.scolding@tesco.net</Email>
            </Contact>
          </Editor>
          <Affiliation ID="AffID1">
            <OrgDivision>Frenchay Hospital</OrgDivision>
            <OrgName>University of Bristol</OrgName>
            <OrgAddress>
              <City>Bristol</City>
              <Postcode>BS16 1LE</Postcode>
              <Country>United Kingdom</Country>
            </OrgAddress>
          </Affiliation>
          <Affiliation ID="AffID2">
            <OrgDivision>Frenchay Hospital</OrgDivision>
            <OrgName>University of Bristol</OrgName>
            <OrgAddress>
              <City>Bristol</City>
              <Postcode>BS16 1LE</Postcode>
              <Country>United Kingdom</Country>
            </OrgAddress>
          </Affiliation>
        </EditorGroup>
      </BookHeader>
      <Part ID="Part1">
        <PartInfo OutputMedium="All" TocLevels="0">
          <PartID>1</PartID>
          <PartSequenceNumber>1</PartSequenceNumber>
          <PartTitle>Introductory Reviews</PartTitle>
          <PartChapterCount>3</PartChapterCount>
          <PartContext>
            <SeriesID>7651</SeriesID>
            <BookID>978-1-60327-931-4</BookID>
            <BookTitle>Neural Cell Transplantation</BookTitle>
          </PartContext>
        </PartInfo>
        <Chapter ID="Chap1" Language="En">
          <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterContentSeparately" OutputMedium="All" TocLevels="0">
            <ChapterID>1</ChapterID>
            <ChapterNumber>1</ChapterNumber>
            <ChapterDOI>10.1007/978-1-60327-931-4_1</ChapterDOI>
            <ChapterSequenceNumber>1</ChapterSequenceNumber>
            <ChapterTitle Language="En">Neural Transplantation and Stem Cells</ChapterTitle>
            <ChapterFirstPage>3</ChapterFirstPage>
            <ChapterLastPage>16</ChapterLastPage>
            <ChapterCopyright>
              <CopyrightHolderName>Humana Press, a part of Springer Science+Business Media, LLC</CopyrightHolderName>
              <CopyrightYear>2009</CopyrightYear>
            </ChapterCopyright>
            <ChapterHistory>
              <RegistrationDate>
                <Year>2009</Year>
                <Month>1</Month>
                <Day>5</Day>
              </RegistrationDate>
              <OnlineDate>
                <Year>2009</Year>
                <Month>3</Month>
                <Day>23</Day>
              </OnlineDate>
            </ChapterHistory>
            <ChapterGrants Type="Regular"><MetadataGrant Grant="OpenAccess"/><AbstractGrant Grant="OpenAccess"/><BodyPDFGrant Grant="Restricted"/><BodyHTMLGrant Grant="Restricted"/><BibliographyGrant Grant="Restricted"/><ESMGrant Grant="Restricted"/></ChapterGrants><ChapterContext>
              <SeriesID>7651</SeriesID>
              <PartID>1</PartID>
              <BookID>978-1-60327-931-4</BookID>
              <BookTitle>Neural Cell Transplantation</BookTitle>
            </ChapterContext>
          </ChapterInfo>
          <ChapterHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1_1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Mahendra</GivenName>
                  <GivenName>S.</GivenName>
                  <FamilyName>Rao</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1_1" CorrespondingAffiliationID="Aff1_1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Mohan</GivenName>
                  <GivenName>C.</GivenName>
                  <FamilyName>Vemuri</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>mohan.vemuri@invitrogen.com</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1_1">
                <OrgName>Invitrogen Corporation</OrgName>
                <OrgAddress>
                  <Street>3175 Staley Road</Street>
                  <Postcode>14072</Postcode>
                  <City>Grand Island</City>
                  <State>NY</State>
                  <Country>USA</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1_1" Language="En" OutputMedium="All">
              <Heading>Summary</Heading>
              <Para>Recent results have raised important questions on our ability to amplify stem cell populations in sufficient numbers as to be useful for therapy. Several reports have indicated that human stem cell populations harvested from the adult have low or undetectable telomerase levels, age in culture, and may not be propagated indefinitely. Other groups have shown that stem cells age and as such, their properties will have changed depending on the age of the individual from which they are harvested, and the time for which they are propagated in culture. Other groups have shown that cells maintained in culture may undergo alterations as they are propagated, and that these alterations may alter the predicted behavior of stem cells. Yet others have shown that human cells differ from their counterparts in other species in significant ways and have identified important difficulties in assessing cells in a xeno environment. Clinical colleagues have identified issues of variability and difficulties in the long-term follow-up that is being requested. Researchers in the stem cell field focused on translational work need to develop a practical plan that takes into account such difficulties while developing manufacturing protocols, designing animal studies, or developing trial protocols. Such proactive planning will be critical in ensuring a successful transition from the bench to the clinic.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Key words</Heading>
              <Keyword>Neural stem cells</Keyword>
              <Keyword>Stem cell</Keyword>
              <Keyword>Transplantation</Keyword>
              <Keyword>Cell therapy</Keyword>
              <Keyword>Clinical trials</Keyword>
              <Keyword>Immune response</Keyword>
              <Keyword>Adult stem cells</Keyword>
              <Keyword>Animal models</Keyword>
            </KeywordGroup>
          </ChapterHeader>
          <Body>
            <Section1 ID="Sec1_1">
              <Heading>Introduction</Heading>
              <Para>Cells irrespective of the investigators preference of type (stem, progenitor, or differentiated cell) are thought to help enhance repair in the nervous system by one or a subset of the mechanisms described (<Emphasis Type="Bold">Table</Emphasis>
                <InternalRef RefID="Tab1">1</InternalRef>). Based on their proposed mechanism several practical issues become important in evaluating how cell therapy will be performed (<CitationRef CitationID="CR12_1">12</CitationRef>). These practical issues may include important decisions as to whether cell type A or B is preferred, what dose and at what stage in the disease process intervention should be contemplated, what safety studies should be performed, and what readouts of efficacy are most suitable. Subsequent chapters in this book provide detailed methodologies covering specific cell types, methods of analysis, protocols for assessment of cells, and methods of inserting cells to their specific targets.<Table Float="Yes" ID="Tab1">
                  <Caption Language="En">
                    <CaptionNumber>Table 1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Methods of neural differentiation</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="2">
                    <colspec colname="c0" colnum="0"/>
                    <colspec colname="c1" colnum="1"/>
                    <thead>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Methods</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Refs</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Direct differentiation</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>
(<CitationRef CitationID="CR1_1">1</CitationRef>–<CitationRef CitationID="CR3_1">3</CitationRef>)
</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>EB formation</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>
(<CitationRef CitationID="CR4_1">4</CitationRef>)
</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>RA treatment</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>
(<CitationRef CitationID="CR2_1">2</CitationRef>, <CitationRef CitationID="CR5_1">5</CitationRef>)
</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Growth factor withdrawal</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>
(<CitationRef CitationID="CR5_1">5</CitationRef>, <CitationRef CitationID="CR6_1">6</CitationRef>)
</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Coculture with astrocytes of PA-6</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>
(<CitationRef CitationID="CR7_1">7</CitationRef>, <CitationRef CitationID="CR8_1">8</CitationRef>)
</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Stochastic differentiation followed by selection using cell surface epitopes</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>
(<CitationRef CitationID="CR9_1">9</CitationRef>–<CitationRef CitationID="CR11_1">11</CitationRef>)
</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                </Table>
              </Para>
              <Para>In this introductory chapter we will not discuss a particular disease model in detail or provide detailed protocols but rather provide certain general guidelines that appear to have a reasonable consensus. In general there is no “one size fits all” cell for therapy and there is no optimal generalized method of cell delivery. However, there are certain generalized issues that one has to face irrespective of the cell type chosen and the therapeutic target. These are discussed briefly in subsequent sections.</Para>
            </Section1>
            <Section1 ID="Sec2_1">
              <Heading>Autologous Versus Allogeneic Cell Use for Therapy</Heading>
              <Para>Beginning from the 1990s, researchers have actively begun to search for possible cell resources and the cell repertoire has been enlarged in the past 10 years (<CitationRef CitationID="CR13_1">13</CitationRef>). Fetal cells, adult stem cells, a variety of lineage-specific precursor cells, cells transdifferentiated from other tissues or derived from embryonic stem cells (ESCs) have all begun to be used in animal studies and their characteristics have been clarified and evaluated for potential cell therapy sources. The number of cell populations used in animal model is quite remarkable and there is evidence of possible successful functional recovery in a number of disease models. There is in general no dispute among scientists of the utility of adult stem cells and their potential therapeutic role (<CitationRef CitationID="CR14_1">14</CitationRef>). Indeed the only stem cells or stem cell-containing products in clinical use are those derived from adult populations. Bone marrow transplants, limbal stem cell therapy, cord blood transplants, pancreatic islet transplants, and carticell (a cartilage progenitor product) are all examples of successful adult stem or progenitor cell therapy. In contrast, while ESC from mice have been used successfully to derive transgenics and chimeras and we have known about mouse ESC since the 1980s no ESC or ESC product is currently used in the clinic (<CitationRef CitationID="CR15_1">15</CitationRef>, <CitationRef CitationID="CR16_1">16</CitationRef>).</Para>
              <Para>Perhaps the most important choice that investigators need to make is to determine if one will work with autologous or allogeneic cells (<Emphasis Type="Bold">Table</Emphasis>
                <InternalRef RefID="Tab2">2</InternalRef>). Indeed, the entire therapeutic paradigm changes when one considers including immune suppression (or demonstrating that these cells are not rejected) and as such the cost, follow, and even possible therapeutic targets need to be reevaluated. In addition, the regulatory environment treats such therapies differently as well. In the USA autologous cells are governed under different sections of the relevant PHS act (with exceptions depending on whether they are manipulated in culture and if the use is homologous or nonhomologous). The EU regulations similarly regulate allogenic and autologous cell types differently. In general the regulations are much more stringent for allogeneic therapy and to our knowledge no research investigator has initiated a clinical trial with allogeneic cells (<CitationRef CitationID="CR17_1">17</CitationRef>, <CitationRef CitationID="CR18_1">18</CitationRef>). Thus, on a practical level this is the most important distinction that a researcher needs to make as he/she proceeds to the clinic.<Table Float="Yes" ID="Tab2">
                  <Caption Language="En">
                    <CaptionNumber>Table 2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Problems facing investigators</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="2">
                    <colspec colname="c0" colnum="0"/>
                    <colspec colname="c1" colnum="1"/>
                    <thead>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Problems facing investigators</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Comments</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry colname="c0">
                          <SimplePara>CMC issues</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Xeno issues, lot-to-lot variability, release criteria, measures of potency and efficacy</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Animal model issues</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Is the model appropriate? Are primate models critical? Can human-to-human transplants be modeled in human to mouse experiments?</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Tracking and tracing and follow-up issues</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Biodistribution, tumor formation studies, labeling</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Patient selection criteria</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Allelic variability, long-term immune suppression, methods of delivery</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Tracking and tracing and follow-up issues in patients</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Noninvasive monitoring, engineering suicide genes, etc.</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                </Table>
              </Para>
            </Section1>
            <Section1 ID="Sec3_1">
              <Heading>Scale-Up and Manufacturability</Heading>
              <Para>Regenerative medicine and cell therapy are based on the premise that large numbers of “normal” cells will be available from adult, fetal, or embryonic sources and that these cells will migrate, integrate, and survive for a sufficient length of time as to be clinically useful. It has become clear that such large numbers of cells are not available by direct harvest from a donor source but require at least limited propagation in culture. Thus, an important issue facing investigators is growing cells in sufficient numbers for treating patients in an aseptic environment with adequate safeguards, sterility, and traceability (<Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig1">1</InternalRef>). Guidelines for the manufacture of biologic have been developed and codified under CMC (chemistry and manufacturing controls) and GMP (good manufacturing practices) guidelines. While expertise on CMC and GMP practices is widespread given the use of antibodies, viral gene delivery, and peptide and growth factor treatment there are nevertheless several additional issues with the use of cells in general and stem cells in particular (<CitationRef CitationID="CR16_1">16</CitationRef>, <CitationRef CitationID="CR19_1">19</CitationRef>).<Figure Category="Standard" Float="Yes" ID="Fig1">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Generic scheme for stem cell-based transplant therapy up to phase 1 studies.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-931-4_1_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para>In the case of stem cells an additional issue of stability of the population arises as it is known that the undifferentiated stem cell state is unstable and prone to change as cells are propagated in culture. Indeed, it has been extremely difficult to propagate any human stem cell population over prolonged periods. Hematopoietic stem cells (HSC) and cord blood stem cells are examples of a failure to propagate to any degree while mesenchymal stem cells (MSC) are examples of adult stem cell with a limited proliferation potential. However, as discussed earlier, a critical requirement for cell therapy is the ability to maintain cells as a stable self-renewing population that retains the ability to differentiate into the cell type required.</Para>
              <Para>It is equally important to develop a set of quality control procedures that will allow assessment of the state of the cells ­rapidly without using too many cells. This includes testing the major phenotypic changes that might be predictive of an alteration in cell behavior. A list of measurements we have proposed is listed in <Emphasis Type="Bold">Table</Emphasis>
                <InternalRef RefID="Tab3">3</InternalRef>. Our rationale for their selection was based on the assump­tion that cells maintained in culture are under constant selection pressure to divide and self-renew, and that changes can occur in a stochastic manner under all culture conditions (<CitationRef CitationID="CR15_1">15</CitationRef>, <CitationRef CitationID="CR20_1">20</CitationRef>, <CitationRef CitationID="CR21_1">21</CitationRef>). Severely detrimental mutations that do not confer a growth advantage will be lost, while those that inhibit death, accelerate growth, or alter differentiation will be selected for. In addition, if a cell undergoes sufficient passage these changes will become fixed in the genome or epigenome and the cells will be irretrievably changed over time. Such changes and such selection have been observed with cell lines and with mouse ESC cultures, and we reason that human stem cells would also undergo such selection pressure. We therefore feel that measuring the functional ability of cells, their expression profiles of key genes (telomerase, cell cycle, key markers of the ESC state, etc.), genomic stability, and epigenome (methylation, miRNA, histone acetylation, X chromosome inactivation) would be a reasonable set of tests that need to be performed. Histone modification and DNA methylation are the most commonly measured epigenetic changes (<CitationRef CitationID="CR22_1">22</CitationRef>–<CitationRef CitationID="CR24_1">24</CitationRef>); both types of analysis are labor-intensive although array-based methods in development have the potential to allow inexpensive assessment of the methylation status of hundreds of regulatory elements.<Table Float="Yes" ID="Tab3">
                  <Caption Language="En">
                    <CaptionNumber>Table 3</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Best characterized differences between human and rodent stem cells</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="3">
                    <colspec colname="c0" colnum="0"/>
                    <colspec colname="c1" colnum="1"/>
                    <colspec colname="c2" colnum="2"/>
                    <thead>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Embryonic stem cells</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Rodents</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Humans</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry nameend="c2" namest="c0">
                          <SimplePara>
                            <Emphasis Type="Italic">Growth Characteristics</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Colony morphology</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Piled</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Flat</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Distinct Borders for colony</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Population doubling time</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>12 h</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>36 h</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Cloning efficiency</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Good</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Difficult</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry nameend="c2" namest="c0">
                          <SimplePara>
                            <Emphasis Type="Italic">Cell surface and other antigens</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>LIF dependence</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>−</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>LIF receptor-gp 130</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>−</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>LIF signaling inhibition by SOCSI</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>FGF2 dependence</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>FGF4</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>−</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>SSEA1</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>−</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>SSEA3</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>SSEA4</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>TRA-1–61</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>TRA-1–81</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>GCTM-2</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>CD9</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>CD133</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>OCT 4</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Nanog</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Sox2</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>β-III tubulin</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Low levels</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Integrins</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>α5, α6, β1</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>α6, α1,β1,β2,β3,β4</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry nameend="c2" namest="c0">
                          <SimplePara>
                            <Emphasis Type="Italic">Enzyme activities</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Alkaline phosphatase</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Telomerase</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Neural <Emphasis Type="Bold">s</Emphasis>tem <Emphasis Type="Bold">c</Emphasis>ells</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Rodents</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Humans</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry nameend="c2" namest="c0">
                          <SimplePara>
                            <Emphasis Type="Italic">Growth characteristics</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Timing of appearance</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>E10.5</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>5 weeks</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Astrocyte appearance</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Late</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Early</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Cell cycle, number of divisions</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Short</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Long</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry nameend="c2" namest="c0">
                          <SimplePara>
                            <Emphasis Type="Italic">Cell surface and other antigens</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>NGF,PDGF,CNTF, LIF</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>Differ</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Differ</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>MHC class 1 expression</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+; high level early on</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>CD95</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Glial –A2B5 marker</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+in cortical NPCs</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Olig-2</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>−/?; likely in cultures</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>NG-2</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>−</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Glial GFAP in NSC</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>− fetal NSC</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>−</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Nestin</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>SOX2</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>+</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>+</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>O4/GALC</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>−</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Oct4</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>−</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry nameend="c2" namest="c0">
                          <SimplePara>
                            <Emphasis Type="Italic">Enzyme activities</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Neuron-specific enolase</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>?</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Carbonic anhydrase</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>−</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>?</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c0">
                          <SimplePara>Telomerase</SimplePara>
                        </entry>
                        <entry colname="c1">
                          <SimplePara>High</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>low</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                </Table>
              </Para>
              <Para>A third issue facing investigators is eliminating unwanted cells from the sample cell population. In the case of undifferentiated stem cells, it has also become evident that undifferentiated cells are often not the best choice for therapy and that appropriate phenotypes must be differentiated from them, for example, differentiating ESCs to neural or glial cell types (<Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig2">2</InternalRef>). The population of desired cells then needs to be harvested away from contaminating undifferentiated cells and other inappropriate or undesirable differentiated cell populations.<Figure Category="Standard" Float="Yes" ID="Fig2">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Scheme for differentiation of human embryonic stem cells into neural cell types and isolation of cells needed for transplantation through cell sorting.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-931-4_1_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para>A final issue that faces investigators is a more subtle one and that is, given the inevitable lot-to-lot variability (even if one is using stem cells) will results from a clinical trial by one group allow another to extrapolate to cells manufactured at a different site or by another company? In Battens disease will a second company’s trial for neural stem cells be like what one would do for a generic drug or modification of an existing drug given the pioneering work of Stem Cell, Inc. or will any new stem cell product be treated like a new drug.</Para>
              <Para>Conceptually then a manufacturing protocol consists of a master bank of undifferentiated cells that have been carefully tested to assure their quality from which working lots of cells are withdrawn, amplified to obtain sufficient numbers of cells, differentiated, and an appropriate phenotype selected based on established criteria (<Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig3"> 3</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig3">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 3</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Cell manufacturing protocols in cGMP and scale-up conditions.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-931-4_1_Fig3_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                  </MediaObject>
                </Figure>
              </Para>
            </Section1>
            <Section1 ID="Sec4_1">
              <Heading>Determining Cell Numbers for Therapy</Heading>
              <Para>In addition to determining the specific cell type to be used, one will also need to determine at what stage of differentiation the cells should be transplanted and more importantly what is the dose range of cells that one will use. The decisions on the type of cell to be used, the cell numbers to be used, and the method of delivery that will be optimum will vary. For example, the number of cells to be used in Parkinson’s therapy would range between 100,000 and 500,000 and would likely be delivered via a needle into the parenchyma guided by MRI (<CitationRef CitationID="CR25_1">25</CitationRef>). Primarily dopaminergic neurons to the exclusion of all other cells would be important if the intent was to replace the damaged or lost dopaminergic neurons. The numbers and type of cell would be altered even for Parkinson’s disease if one contemplated using stem cells or their derivatives as pumps to deliver a growth factor to enhance survival of existing neurons. In this case migration would not be a useful property and homing to a stem cell niche, for example, would be a disadvantage. In spinal cord injury, on the other hand, delivery may be parenchymal or via lumbar puncture (outpatient procedure) with a consequent difference in numbers of cell required. Since neuronal replacement would not be as important as glial replacement, the cell selected should preferably have limited neuronal differentiation (to limit aberrant neural circuit formation) and the cells should have a limited migration potential. This migratory ability should it exist, should preferably be directed toward a lesion. In stroke, given the domain is large ­perhaps intravenous or intra-arterial delivery may be contemplated despite the known embolic risks. In this case the ability of a cell to migrate through the blood vessel into the parenchyma and the ability to migrate to a target site may be invaluable properties.</Para>
            </Section1>
            <Section1 ID="Sec5_1">
              <Heading>Assessing Mode of Action</Heading>
              <Para>There are several aspects to this issue. Perhaps the most obvious is simply how does one trace cells, assess biodistribution, and quantify integrated cells. These issues while more difficult to address than assessing small molecules are nevertheless conceptually similar and we have tools and techniques to assess such issues: radioactive labeling of cells to look at short-term distribution, contrast labels to follow cells over longer time periods, and multiple methods to assess integration. However, there are also more subtle issues that one needs to consider in assessing mode of action in animal models (<Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig4">4</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig4">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 4</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Transplantation into animal models and relevant issues for clinical application.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-931-4_1_Fig4_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para>Perhaps the most important is the issue of immune suppression and evaluating this in animal models. Testing human cells in animals requires manipulating the endogenous rejection response to a xenotransplant, and thus studying immune rejection issues that may relate to transplanting allelically mismatched cells from one human donor to another cannot be readily tested. Yet this is a critical issue, despite many reports that stem cells may not be immunogenic or may suppress a MLR reaction (<CitationRef CitationID="CR26_1">26</CitationRef>, <CitationRef CitationID="CR27_1">27</CitationRef>
                <Emphasis Type="BoldItalic">).</Emphasis> It is clear that long-term survival requires some sort of immune suppression. Perhaps the only solution has been to test equivalent rat/mouse cells from a different strain in rat/mouse model. Yet even this is not very satisfying as there are many reported differences between stem cells isolated from different species (<CitationRef CitationID="CR17_1">17</CitationRef>, <CitationRef CitationID="CR28_1">28</CitationRef>, <CitationRef CitationID="CR29_1">29</CitationRef>) even if care is taken to isolate them by similar methods, at similar stages of development and maintain them in similar conditions.</Para>
              <Para>The second critical issue is what we have euphemistically termed the xeno issue. Transplanting human cells in an animal model is simply not the same as transplanting human cells into human (<CitationRef CitationID="CR26_1">26</CitationRef>). The reason is that no matter how similar the disease model there are a host of physiological factors that are different: the size of the cells, their cycle time, osmolarity, and endocrine differences, blood pressure and heart rate variation, and even tissue oxygen concentration. Each of these differences has cumulative effects on cells affecting their survival or efficiency of integration and has no bearing on the issue of human cells transplanted into humans. The second alternative is to consider same species cells into the appropriate model as a test for human-to-human transplants is also not optimal. Species differences between cells are well known in either marker expression, growth factor response, or sensitivity to toxins (<CitationRef CitationID="CR17_1">17</CitationRef>). In addition, there is limited availability of large-scale models or equivalent cells types in many species. For example, we do not have any data that rat ESCs are available, behave the same way, or respond to the same growth factors. However, the rat is a very useful model for neural assessment. One, therefore, faces a dilemma of how one may perform realistic tests that the FDA will find appropriate.</Para>
            </Section1>
            <Section1 ID="Sec6_1">
              <Heading>Determining a Clinical End Point and Assessing Patient Recruitment Criteria</Heading>
              <Para>As with any clinical trial there are several issues that are common to using stem cells or a small molecule drug. These include appropriate patient selection, obtaining appropriate consent, and determining the number of patients required to obtain interpretable results from clinical trials (<Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig5">5</InternalRef>). These are well discussed elsewhere. We focus on two issues that we feel are relatively unique to stem cell populations.<Figure Category="Standard" Float="Yes" ID="Fig5">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 5</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Clinical study issues with stem cells.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-931-4_1_Fig5_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para>The first issue is the lot size. Generally, when autologous therapy is considered each lot is used for one patient. Even in many of the autologous therapies that are being considered lot sizes are often small and are sufficient to treat only a small number of patients (<CitationRef CitationID="CR30_1">30</CitationRef>). This brings up an important issue for regulators and for investigators. How does one predict the effect and efficacy from lot to lot as there is undoubtedly variability when cells are harvested from different donors or different ages, different ethnic backgrounds, and different clinical histories and environmental exposures? An extension of this issue is determining the size of a clinical trial when such variability is likely to be confounding.</Para>
              <Para>A second equally important issue that all of us face is the issue of the half-life of cells and their change after transplant. Unlike drugs that have a relatively short half-life and that are metabolized by relatively well-characterized pathways, cells are rather different. Stem cells may persist for the lifetime of an individual and for the most part respond to the environment by changing or differentiating. This differentiation is regulated by the environment, which, in most currently envisaged uses, is a nonhomologous use of a stem cell.</Para>
              <Para>A third major issue for stem cell therapy is not knowing the mechanism of action and therefore being unable to design appropriate efficacy assays and generate a dosing regime or selecting the right patients for therapy. Stem cells may integrate and replace missing cells; stem cells may mobilize endogenous repair pathways, and stem cells may provide trophic support or may do all of the aforementioned functions (<CitationRef CitationID="CR31_1">31</CitationRef>, <CitationRef CitationID="CR32_1">32</CitationRef>). This makes designing a clinical trial quite difficult as one does not quite know how many cells to transplant, how to test the quality of the cells that will predict their efficacy with reasonable efficiency, how long to follow, and how large a trial will be to have appropriate interpretable results. This has a major impact on the cost of a trial, recruitment of patients, and the ability of regulators to interpret these trials fairly. These difficulties have suggested that the standard model that we use for drug trial may not be the best for cells. Unfortunately, we do not have a better alternative that would not put patients at significant risk.</Para>
            </Section1>
            <Section1 ID="Sec7_1">
              <Heading>Translating These Concerns into Practical Solutions</Heading>
              <Para>Most therapeutic uses of stem cells require large number of cells maintained in a GMP facility. Likewise, for gene and drug discovery processes, it is assumed that stable and genetically identical cells will be available in large numbers. A flow chart of the choices that need to made is summarized (<Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig1">1</InternalRef>). Perhaps the first choice is whether therapy will be autologous or allogeneic and whether amplification in culture will be required or not. If no amplification is required and the cells are minimally manipulated then processing will be straightforward and regulatory hurdles will be clear-cut. Should amplification of cells be required or cells have to be altered (transdifferentiated) for their function then even if autologous cells are used they will need to be processed in a GMP facility adhering to rigorous guidance. The emerging approach for CMC manufacture is to develop a master bank from which a working bank of cells is obtained and differentiated into an appropriate phenotype for use. Cells are selected based on cell surface epitopes using a GMPable process and a closed isolation system such as the Isolex/Dynal or Clinimacs systems. Once sufficient cells are obtained animal studies will be performed ideally with cells harvested by a GMPable process (if not in a GMP ­facility), and tests on the biodistribution and safety will be performed in an appropriate animal model that takes into account known ­species differences and the problems of transplanting human cells in an alien environment. Novel methods to follow transplanted cells and assess their biodistribution safety and efficacy will be utilized and corresponding noninvasive tests will be used in ­clinical trials where monitoring will be of a sufficient time period to satisfy concerns of tumorigenicity and toxicity of any kind.</Para>
            </Section1>
          </Body>
          <BodyRef FileRef="BodyRef/PDF/978-1-60327-931-4_Chapter_1.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
          <ChapterBackmatter>
            <Bibliography ID="Bib1_1">
              <Heading>References</Heading>
              <Citation ID="CR1_1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M. K.</Initials>
                    <FamilyName>Carpenter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Rosler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Characterization and differentiation of human embryonic stem cells</ArticleTitle>
                  <JournalTitle>Cloning Stem Cells</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>79</FirstPage>
                  <LastPage>88</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12713704</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/153623003321512193</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXis1eis7k%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Carpenter, M. K., Rosler, E. and Rao, M. S. (2003). Characterization and differentiation of human embryonic stem cells. Cloning Stem Cells 5, 79–88.</BibUnstructured>
              </Citation>
              <Citation ID="CR2_1">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Luo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Schwartz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Shin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Zeng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N.</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Yu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">A focused microarray to assess dopa­minergic and glial cell differentiation from fetal tissue or embryonic stem cells</ArticleTitle>
                  <JournalTitle>Stem Cells</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <FirstPage>865</FirstPage>
                  <LastPage>75</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16357341</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1634/stemcells.2005-0392</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XhtFKiu7rN</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Luo, Y., Schwartz, C., Shin, S., Zeng, X., Chen, N., Wang, Y., Yu, X. and Rao, M. S. (2006). A focused microarray to assess dopa­minergic and glial cell differentiation from fetal tissue or embryonic stem cells. Stem Cells 24, 865–75.</BibUnstructured>
              </Citation>
              <Citation ID="CR3_1">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Zeng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Miura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Luo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Bhattacharya</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Condie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I.</Initials>
                    <FamilyName>Ginis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I.</Initials>
                    <FamilyName>Lyons</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Mejido</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R. K.</Initials>
                    <FamilyName>Puri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W. J.</Initials>
                    <FamilyName>Freed</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Properties of pluripotent human embryonic stem cells BG01 and BG02</ArticleTitle>
                  <JournalTitle>Stem Cells</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>292</FirstPage>
                  <LastPage>312</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15153607</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1634/stemcells.22-3-292</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXlsFCgu7o%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zeng, X., Miura, T., Luo, Y., Bhattacharya, B., Condie, B., Chen, J., Ginis, I., Lyons, I., Mejido, J., Puri, R. K., Rao, M. S. and Freed, W. J. (2004). Properties of pluripotent human embryonic stem cells BG01 and BG02. Stem Cells 22, 292–312.</BibUnstructured>
              </Citation>
              <Citation ID="CR4_1">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H.</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Shin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Sun</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J. F.</Initials>
                    <FamilyName>Loring</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. P.</Initials>
                    <FamilyName>Mattson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Zhan</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Transcriptome coexpression map of human embryonic stem cells</ArticleTitle>
                  <JournalTitle>BMC Genomics</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>103</FirstPage>
                  <Occurrence Type="PID">
                    <Handle>16670017</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/1471-2164-7-103</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Li, H., Liu, Y., Shin, S., Sun, Y., Loring, J. F., Mattson, M. P., Rao, M. S. and Zhan, M. (2006). Transcriptome coexpression map of human embryonic stem cells. BMC Genomics 7, 103.</BibUnstructured>
              </Citation>
              <Citation ID="CR5_1">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Mayer-Proschel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A. J.</Initials>
                    <FamilyName>Kalyani</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Mujtaba</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Isolation of lineage-restricted neuronal precursors from multipotent neuroepithelial stem cells</ArticleTitle>
                  <JournalTitle>Neuron</JournalTitle>
                  <VolumeID>19</VolumeID>
                  <FirstPage>773</FirstPage>
                  <LastPage>85</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9354325</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0896-6273(00)80960-5</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXntFersL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mayer-Proschel, M., Kalyani, A. J., Mujtaba, T. and Rao, M. S. (1997). Isolation of lineage-restricted neuronal precursors from multipotent neuroepithelial stem cells. Neuron 19, 773–85.</BibUnstructured>
              </Citation>
              <Citation ID="CR6_1">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Miura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. P.</Initials>
                    <FamilyName>Mattson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Cellular lifespan and senescence signaling in embryonic stem cells</ArticleTitle>
                  <JournalTitle>Aging Cell</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>333</FirstPage>
                  <LastPage>43</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15569350</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1474-9728.2004.00134.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXhtFSgsrnN</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Miura, T., Mattson, M. P. and Rao, M. S. (2004). Cellular lifespan and senescence signaling in embryonic stem cells. Aging Cell 3, 333–43.</BibUnstructured>
              </Citation>
              <Citation ID="CR7_1">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Ellis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B. M.</Initials>
                    <FamilyName>Fagan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S. T.</Initials>
                    <FamilyName>Magness</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Hutton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>O.</Initials>
                    <FamilyName>Taranova</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Hayashi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>McMahon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Pevny</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Sox2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult</ArticleTitle>
                  <JournalTitle>Dev Neurosci</JournalTitle>
                  <VolumeID>26</VolumeID>
                  <FirstPage>148</FirstPage>
                  <LastPage>65</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15711057</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1159/000082134</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXht1OmsLo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ellis, P., Fagan, B. M., Magness, S. T., Hutton, S., Taranova, O., Hayashi, S., McMahon, A., Rao, M. and Pevny, L. (2004). Sox2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev Neurosci 26, 148–65.</BibUnstructured>
              </Citation>
              <Citation ID="CR8_1">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C. M.</Initials>
                    <FamilyName>Schwartz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C. E.</Initials>
                    <FamilyName>Spivak</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S. C.</Initials>
                    <FamilyName>Baker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T. K.</Initials>
                    <FamilyName>McDaniel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J. F.</Initials>
                    <FamilyName>Loring</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Nguyen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F. J.</Initials>
                    <FamilyName>Chrest</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Wersto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Arenas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Zeng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W. J.</Initials>
                    <FamilyName>Freed</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Ntera2: A model system to study dopaminergic differentiation of human embryonic stem cells</ArticleTitle>
                  <JournalTitle>Stem Cells Dev</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>517</FirstPage>
                  <LastPage>34</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16305337</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/scd.2005.14.517</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXht1GisLjL</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schwartz, C. M., Spivak, C. E., Baker, S. C., McDaniel, T. K., Loring, J. F., Nguyen, C., Chrest, F. J., Wersto, R., Arenas, E., Zeng, X., Freed, W. J. and Rao, M. S. (2005). Ntera2: A model system to study dopaminergic differentiation of human embryonic stem cells. Stem Cells Dev 14, 517–34.</BibUnstructured>
              </Citation>
              <Citation ID="CR9_1">
                <CitationNumber>9.</CitationNumber>
                <BibUnstructured>Shin, S., Sun, Y., Liu, Y., Khaner, H., Svant, S., Cai, J., Xu, X. Q., Davidson, B. P., Stice, S. L., Smith, A. K., Goldman, S. A., Reubinoff, B. E., Zhan, M., Rao, M. S. and Chesnut, J. D. (2007). Whole genome analysis of human neural stem cells derived from embryonic stem cells and stem and progenitor cells isolated from fetal tissue. Stem Cells 25, 1298–306. doi:<ExternalRef><RefSource>10.1634/stemcells.2006-0660</RefSource><RefTarget Address="10.1634/stemcells.2006-0660" TargetType="DOI"/></ExternalRef>.</BibUnstructured>
              </Citation>
              <Citation ID="CR10_1">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D. J.</Initials>
                    <FamilyName>Anderson</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Immortalization and controlled in vitro differentiation of murine multipotent neural crest stem cells</ArticleTitle>
                  <JournalTitle>J Neurobiol</JournalTitle>
                  <VolumeID>32</VolumeID>
                  <FirstPage>722</FirstPage>
                  <LastPage>46</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9183749</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/(SICI)1097-4695(19970620)32:7&lt;722::AID-NEU7&gt;3.0.CO;2-6</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXktFaqtLw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rao, M. S. and Anderson, D. J. (1997). Immortalization and controlled in vitro differentiation of murine multipotent neural crest stem cells. J Neurobiol 32, 722–46.</BibUnstructured>
              </Citation>
              <Citation ID="CR11_1">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Zeng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Deng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J. L.</Initials>
                    <FamilyName>Cadet</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W. J.</Initials>
                    <FamilyName>Freed</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">An in vitro model of human dopaminergic neurons derived from embryonic stem cells: Mpp+ toxicity and gdnf neuroprotection</ArticleTitle>
                  <JournalTitle>Neuropsychopharmacology</JournalTitle>
                  <VolumeID>31</VolumeID>
                  <FirstPage>2708</FirstPage>
                  <LastPage>15</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17109014</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.npp.1301125</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28Xht1SrtbzE</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zeng, X., Chen, J., Deng, X., Liu, Y., Rao, M. S., Cadet, J. L. and Freed, W. J. (2006). An in vitro model of human dopaminergic neurons derived from embryonic stem cells: Mpp+ toxicity and gdnf neuroprotection. Neuropsychopharmacology 31, 2708–15.</BibUnstructured>
              </Citation>
              <Citation ID="CR12_1">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K.</Initials>
                    <FamilyName>Turksen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Issues in human embryonic stem cell biology</ArticleTitle>
                  <JournalTitle>Stem Cell Rev</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>79</FirstPage>
                  <LastPage>81</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17142841</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1385/SCR:1:2:079</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD28jgs1WmtA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Turksen, K. and Rao, M. (2005). Issues in human embryonic stem cell biology. Stem Cell Rev 1, 79–81.</BibUnstructured>
              </Citation>
              <Citation ID="CR13_1">
                <CitationNumber>13.</CitationNumber>
                <BibUnstructured>Magnus, T., Liu, Y., Parker, G. C. and Rao, M. S. (2007). Stem cell myths. Philos Trans R Soc Lond B Biol Sci., in press.</BibUnstructured>
              </Citation>
              <Citation ID="CR14_1">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>I.</Initials>
                    <FamilyName>Ginis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Toward cell replacement therapy: Promises and caveats</ArticleTitle>
                  <JournalTitle>Exp Neurol</JournalTitle>
                  <VolumeID>184</VolumeID>
                  <FirstPage>61</FirstPage>
                  <LastPage>77</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14637081</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0014-4886(03)00256-5</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXptVeksLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ginis, I. and Rao, M. S. (2003). Toward cell replacement therapy: Promises and caveats. Exp Neurol 184, 61–77.</BibUnstructured>
              </Citation>
              <Citation ID="CR15_1">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Choong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Human embryonic stem cells</ArticleTitle>
                  <JournalTitle>Neurosurg Clin N Am</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>1</FirstPage>
                  <LastPage>14</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17244549</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.nec.2006.10.004</Handle>
                  </Occurrence>
                  <BibComments>vii</BibComments>
                </BibArticle>
                <BibUnstructured>Choong, C. and Rao, M. S. (2007). Human embryonic stem cells. Neurosurg Clin N Am 18, 1–14, vii.</BibUnstructured>
              </Citation>
              <Citation ID="CR16_1">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Zeng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Human embryonic stem cells: Long term stability, absence of senescence and a potential cell source for neural replacement</ArticleTitle>
                  <JournalTitle>Neuroscience</JournalTitle>
                  <VolumeID>145</VolumeID>
                  <FirstPage>1348</FirstPage>
                  <LastPage>58</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17055653</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.neuroscience.2006.09.017</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zeng, X. and Rao, M. S. (2006). Human embryonic stem cells: Long term stability, absence of senescence and a potential cell source for neural replacement. Neuroscience 145, 1348–58.</BibUnstructured>
              </Citation>
              <Citation ID="CR17_1">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Sun</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H.</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Shin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. P.</Initials>
                    <FamilyName>Mattson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Zhan</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Cross-species transcriptional profiles establish a functional portrait of embryonic stem cells</ArticleTitle>
                  <JournalTitle>Genomics</JournalTitle>
                  <VolumeID>89</VolumeID>
                  <FirstPage>22</FirstPage>
                  <LastPage>35</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17055697</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ygeno.2006.09.010</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28Xht12jur%2FM</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sun, Y., Li, H., Liu, Y., Shin, S., Mattson, M. P., Rao, M. S. and Zhan, M. (2007). Cross-species transcriptional profiles establish a functional portrait of embryonic stem cells. Genomics 89, 22–35.</BibUnstructured>
              </Citation>
              <Citation ID="CR18_1">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Gibson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P. J.</Initials>
                    <FamilyName>Ho</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D.</Initials>
                    <FamilyName>Joshua</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Evolving transplant options for multiple myeloma: Autologous and nonmyeloablative allogenic</ArticleTitle>
                  <JournalTitle>Transplant Proc</JournalTitle>
                  <VolumeID>36</VolumeID>
                  <FirstPage>2501</FirstPage>
                  <LastPage>3</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15561295</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.transproceed.2004.06.033</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD2crovFSitw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gibson, J., Ho, P. J. and Joshua, D. (2004). Evolving transplant options for multiple myeloma: Autologous and nonmyeloablative allogenic. Transplant Proc 36, 2501–3.</BibUnstructured>
              </Citation>
              <Citation ID="CR19_1">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Terstegge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I.</Initials>
                    <FamilyName>Laufenberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Pochert</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Schenk</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Itskovitz-Eldor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Endl</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>O.</Initials>
                    <FamilyName>Brustle</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Automated maintenance of embryonic stem cell cultures</ArticleTitle>
                  <JournalTitle>Biotechnol Bioeng</JournalTitle>
                  <VolumeID>96</VolumeID>
                  <FirstPage>195</FirstPage>
                  <LastPage>201</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16960892</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/bit.21061</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXjsV2ksQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Terstegge, S., Laufenberg, I., Pochert, J., Schenk, S., Itskovitz-Eldor, J., Endl, E. and Brustle, O. (2007). Automated maintenance of embryonic stem cell cultures. Biotechnol Bioeng 96, 195–201.</BibUnstructured>
              </Citation>
              <Citation ID="CR20_1">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Sun</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H.</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H.</Initials>
                    <FamilyName>Yang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Zhan</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Mechanisms controlling embryonic stem cell self-renewal and differentiation</ArticleTitle>
                  <JournalTitle>Crit Rev Eukaryot Gene Expr</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>211</FirstPage>
                  <LastPage>31</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17073552</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1615/CritRevEukarGeneExpr.v16.i3.20</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28Xht1ehs7rM</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sun, Y., Li, H., Yang, H., Rao, M. S. and Zhan, M. (2006). Mechanisms controlling embryonic stem cell self-renewal and differentiation. Crit Rev Eukaryot Gene Expr 16, 211–31.</BibUnstructured>
              </Citation>
              <Citation ID="CR21_1">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G. C.</Initials>
                    <FamilyName>Parker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Anastassova-Kristeva</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L. M.</Initials>
                    <FamilyName>Eisenberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. A.</Initials>
                    <FamilyName>Williams</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P. R.</Initials>
                    <FamilyName>Sanberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D.</Initials>
                    <FamilyName>English</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Stem cells: Shibboleths of development, Part 2: Toward a functional definition</ArticleTitle>
                  <JournalTitle>Stem Cells Dev</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>463</FirstPage>
                  <LastPage>9</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16305331</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/scd.2005.14.463</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXht1GisLnN</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Parker, G. C., Anastassova-Kristeva, M., Eisenberg, L. M., Rao, M. S., Williams, M. A., Sanberg, P. R. and English, D. (2005). Stem cells: Shibboleths of development, Part 2: Toward a functional definition. Stem Cells Dev 14, 463–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR22_1">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Spivakov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A. G.</Initials>
                    <FamilyName>Fisher</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Epigenetic signatures of stem-cell identity</ArticleTitle>
                  <JournalTitle>Nat Rev Genet</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>263</FirstPage>
                  <LastPage>71</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17363975</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nrg2046</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXivVGktbc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Spivakov, M. and Fisher, A. G. (2007). Epigenetic signatures of stem-cell identity. Nat Rev Genet 8, 263–71.</BibUnstructured>
              </Citation>
              <Citation ID="CR23_1">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Bibikova</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Chudin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Zhou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E. W.</Initials>
                    <FamilyName>Garcia</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Shin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T. W.</Initials>
                    <FamilyName>Plaia</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J. M.</Initials>
                    <FamilyName>Auerbach</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D. E.</Initials>
                    <FamilyName>Arking</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Gonzalez</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Crook</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Davidson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T. C.</Initials>
                    <FamilyName>Schulz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Robins</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Khanna</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Sartipy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Hyllner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Vanguri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Savant-Bhonsale</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A. K.</Initials>
                    <FamilyName>Smith</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Chakravarti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Maitra</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D. L.</Initials>
                    <FamilyName>Barker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J. F.</Initials>
                    <FamilyName>Loring</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J. B.</Initials>
                    <FamilyName>Fan</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Human embryonic stem cells have a unique epigenetic signature</ArticleTitle>
                  <JournalTitle>Genome Res</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>1075</FirstPage>
                  <LastPage>83</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16899657</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1101/gr.5319906</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XpsFelsrw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bibikova, M., Chudin, E., Wu, B., Zhou, L., Garcia, E. W., Liu, Y., Shin, S., Plaia, T. W., Auerbach, J. M., Arking, D. E., Gonzalez, R., Crook, J., Davidson, B., Schulz, T. C., Robins, A., Khanna, A., Sartipy, P., Hyllner, J., Vanguri, P., Savant-Bhonsale, S., Smith, A. K., Chakravarti, A., Maitra, A., Rao, M., Barker, D. L., Loring, J. F. and Fan, J. B. (2006). Human embryonic stem cells have a unique epigenetic signature. Genome Res 16, 1075–83.</BibUnstructured>
              </Citation>
              <Citation ID="CR24_1">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Miura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Luo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I.</Initials>
                    <FamilyName>Khrebtukova</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Brandenberger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D.</Initials>
                    <FamilyName>Zhou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R. S.</Initials>
                    <FamilyName>Thies</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Vasicek</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H.</Initials>
                    <FamilyName>Young</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Lebkowski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. K.</Initials>
                    <FamilyName>Carpenter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Monitoring early differentiation events in human embryonic stem cells by massively parallel signature sequencing and expressed sequence tag scan</ArticleTitle>
                  <JournalTitle>Stem Cells Dev</JournalTitle>
                  <VolumeID>13</VolumeID>
                  <FirstPage>694</FirstPage>
                  <LastPage>715</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15684837</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/scd.2004.13.694</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXnt1Wruw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Miura, T., Luo, Y., Khrebtukova, I., Brandenberger, R., Zhou, D., Thies, R. S., Vasicek, T., Young, H., Lebkowski, J., Carpenter, M. K. and Rao, M. S. (2004). Monitoring early differentiation events in human embryonic stem cells by massively parallel signature sequencing and expressed sequence tag scan. Stem Cells Dev 13, 694–715.</BibUnstructured>
              </Citation>
              <Citation ID="CR25_1">
                <CitationNumber>25.</CitationNumber>
                <BibUnstructured>Takahashi, J. (2006). Stem cell therapy for Parkinson’s disease. Ernst Schering Res Found Workshop 229–44.</BibUnstructured>
              </Citation>
              <Citation ID="CR26_1">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Bonnevie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Bel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Sabbah</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N.</Initials>
                    <FamilyName>Al Attar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Pradeau</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Weill</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F.</Initials>
                    <FamilyName>Le Deist</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V.</Initials>
                    <FamilyName>Bellamy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Peyrard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Menard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Desnos</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Bruneval</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Binder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A. A.</Initials>
                    <FamilyName>Hagege</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Puceat</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Menasche</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Is xenotransplantation of embryonic stem cells a realistic option?</ArticleTitle>
                  <JournalTitle>Transplantation</JournalTitle>
                  <VolumeID>83</VolumeID>
                  <FirstPage>333</FirstPage>
                  <LastPage>5</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17297408</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/01.tp.0000247798.68218.29</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bonnevie, L., Bel, A., Sabbah, L., Al Attar, N., Pradeau, P., Weill, B., Le Deist, F., Bellamy, V., Peyrard, S., Menard, C., Desnos, M., Bruneval, P., Binder, P., Hagege, A. A., Puceat, M. and Menasche, P. (2007). Is xenotransplantation of embryonic stem cells a realistic option? Transplantation 83, 333–5.</BibUnstructured>
              </Citation>
              <Citation ID="CR27_1">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Z.</Initials>
                    <FamilyName>Hewitt</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H.</Initials>
                    <FamilyName>Priddle</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A. J.</Initials>
                    <FamilyName>Thomson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D.</Initials>
                    <FamilyName>Wojtacha</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>McWhir</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Ablation of undifferentiated human embryonic stem cells: Exploiting innate immunity against the gal alpha1–3galbeta1–4glcnac-r (alpha-gal) epitope</ArticleTitle>
                  <JournalTitle>Stem Cells</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>10</FirstPage>
                  <LastPage>18</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16960131</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1634/stemcells.2005-0481</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXhvVGjsLY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hewitt, Z., Priddle, H., Thomson, A. J., Wojtacha, D. and McWhir, J. (2007). Ablation of undifferentiated human embryonic stem cells: Exploiting innate immunity against the gal alpha1–3galbeta1–4glcnac-r (alpha-gal) epitope. Stem Cells 25, 10–18.</BibUnstructured>
              </Citation>
              <Citation ID="CR28_1">
                <CitationNumber>28.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>I.</Initials>
                    <FamilyName>Ginis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Luo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Miura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Thies</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Brandenberger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Gerecht-Nir</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Amit</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Hoke</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. K.</Initials>
                    <FamilyName>Carpenter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Itskovitz-Eldor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Differences between human and mouse embryonic stem cells</ArticleTitle>
                  <JournalTitle>Dev Biol</JournalTitle>
                  <VolumeID>269</VolumeID>
                  <FirstPage>360</FirstPage>
                  <LastPage>80</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15110706</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ydbio.2003.12.034</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXjsVaqurg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ginis, I., Luo, Y., Miura, T., Thies, S., Brandenberger, R., Gerecht-Nir, S., Amit, M., Hoke, A., Carpenter, M. K., Itskovitz-Eldor, J. and Rao, M. S. (2004). Differences between human and mouse embryonic stem cells. Dev Biol 269, 360–80.</BibUnstructured>
              </Citation>
              <Citation ID="CR29_1">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Zhan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Miura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Xu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Conservation and variation of gene regulation in embryonic stem cells assessed by comparative genomics</ArticleTitle>
                  <JournalTitle>Cell Biochem Biophys</JournalTitle>
                  <VolumeID>43</VolumeID>
                  <FirstPage>379</FirstPage>
                  <LastPage>405</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16244364</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1385/CBB:43:3:379</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXht1ehsbfK</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zhan, M., Miura, T., Xu, X. and Rao, M. S. (2005). Conservation and variation of gene regulation in embryonic stem cells assessed by comparative genomics. Cell Biochem Biophys 43, 379–405.</BibUnstructured>
              </Citation>
              <Citation ID="CR30_1">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M. H.</Initials>
                    <FamilyName>Qazilbash</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R. M.</Initials>
                    <FamilyName>Saliba</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Hosing</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F.</Initials>
                    <FamilyName>Mendoza</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S. R.</Initials>
                    <FamilyName>Qureshi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D. M.</Initials>
                    <FamilyName>Weber</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Flosser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D. R.</Initials>
                    <FamilyName>Couriel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>De Lima</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Kebriaei</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>U.</Initials>
                    <FamilyName>Popat</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A. M.</Initials>
                    <FamilyName>Alousi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R. E.</Initials>
                    <FamilyName>Champlin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S. A.</Initials>
                    <FamilyName>Giralt</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma</ArticleTitle>
                  <JournalTitle>Bone Marrow Transplant</JournalTitle>
                  <VolumeID>39</VolumeID>
                  <FirstPage>279</FirstPage>
                  <LastPage>83</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17262062</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.bmt.1705580</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD2s7htFagtw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Qazilbash, M. H., Saliba, R. M., Hosing, C., Mendoza, F., Qureshi, S. R., Weber, D. M., Wang, M., Flosser, T., Couriel, D. R., De Lima, M., Kebriaei, P., Popat, U., Alousi, A. M., Champlin, R. E. and Giralt, S. A. (2007). Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39, 279–83.</BibUnstructured>
              </Citation>
              <Citation ID="CR31_1">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Molcayni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K.</Initials>
                    <FamilyName>Bentz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Maegele</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Simanski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Carlitscheck</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Schneider</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Hescheler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Bouillon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>U.</Initials>
                    <FamilyName>Schafer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Neugebauer</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Embryonic stem cell transplantation after experimental traumatic brain injury dramatically improves neurological outcome, but may cause tumors</ArticleTitle>
                  <JournalTitle>J Neurotrauma</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <FirstPage>216</FirstPage>
                  <LastPage>25</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/neu.2006.0141</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Molcayni, M., Bentz, K., Maegele, M., Simanski, C., Carlitscheck, C., Schneider, A., Hescheler, J., Bouillon, B., Schafer, U. and Neugebauer, E. (2007). Embryonic stem cell transplantation after experimental traumatic brain injury dramatically improves neurological outcome, but may cause tumors. J Neurotrauma 24, 216–25.</BibUnstructured>
              </Citation>
              <Citation ID="CR32_1">
                <CitationNumber>32.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Cheng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Coksaygan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H.</Initials>
                    <FamilyName>Tang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Khatri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R. J.</Initials>
                    <FamilyName>Balice-Gordon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M. P.</Initials>
                    <FamilyName>Mattson</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Truncated tyrosine kinase b brain-derived neurotrophic factor receptor directs cortical neural stem cells to a glial cell fate by a novel signaling mechanism</ArticleTitle>
                  <JournalTitle>J Neurochem</JournalTitle>
                  <VolumeID>100</VolumeID>
                  <FirstPage>1515</FirstPage>
                  <LastPage>30</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17286628</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXjsF2rtrg%3D</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1471-4159.2006.04337.x</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Cheng, A., Coksaygan, T., Tang, H., Khatri, R., Balice-Gordon, R. J., Rao, M. S. and Mattson, M. P. (2007). Truncated tyrosine kinase b brain-derived neurotrophic factor receptor directs cortical neural stem cells to a glial cell fate by a novel signaling mechanism. J Neurochem 100, 1515–30.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ChapterBackmatter>
        </Chapter>
      </Part>
    </Book>
  </Series>
</Publisher>